As part of the Trump administration’s efforts aimed at stopping DEI, the government has been restricting how it monitors ...

Fatty acids and other food compounds may change disease activity among individuals with inflammatory bowel diseases.

Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.